- Rating
- 2
- Confidence
- 2
- Informativeness
- 2
- Presentation
- 2
- Soundness
- 2
Read review
Paper summary
This paper proposes AbFUSE, a training-free framework for jointly optimizing antibody sequences against a positive target and multiple negative targets using frozen structure and affinity predictors. The method combines a positive-target binding preservation penalty, an optional local relation term, and a charged-patch objective for CAR-related applications. The authors evaluate AbFUSE on a 37-target computational benchmark and explore multi-target predictions in a STEAP family case study. However, none of the evaluated AbFUSE benchmark runs pass the predefined interface-confidence gate. The exploratory STEAP results show some predicted target-preference signals, but similar patterns are observed in baseline methods, and no experimental binding or selectivity measurements are provided.
Critical strengths
-
Well-motivated multi-objective formulation. The paper addresses a relevant challenge in antibody optimization by considering positive-target binding preservation, negative-target suppression, and optional CAR-related sequence properties within a unified framework. The use of frozen predictors and a shared sequence representation provides a flexible approach to coordinating these objectives.
-
Transparent evaluation and discussion of limitations. The authors clearly distinguish between accepted candidates and exploratory predictions, report unsuccessful screening outcomes, and avoid interpreting computational scores as evidence of experimental binding or selectivity. This transparency helps readers understand the current capabilities and limitations of the proposed framework.
Critical weaknesses
-
Limited evidence of successful antibody optimization. Although the proposed framework is well motivated, none of the 140 evaluable benchmark runs pass the predefined interface-confidence gate, and the STEAP experiments also fail to produce accepted candidates. Consequently, the experiments do not demonstrate that AbFUSE can reliably generate candidates satisfying its intended design constraints. This substantially limits the evidence for the practical effectiveness of the framework.
-
Insufficient validation of multi-target selectivity. The STEAP case study provides exploratory predictions, but the observed preference for STEAP1 over STEAP2/3 also appears in the baseline methods. Moreover, the reported predictions do not establish improved selectivity relative to the original antibody or demonstrate the benefit of joint positive- and negative-target optimization. As a result, the central advantage of the multi-target formulation remains insufficiently supported.
Questions for authors
-
Could the authors further clarify the main factors responsible for these failures? In particular, is there evidence that the optimization improves positive-target interface quality relative to the initial sequences, even when the final candidates fail the predefined threshold?
-
Could the authors clarify what evidence specifically supports the benefit of joint positive- and negative-target optimization in AbFUSE, rather than reflecting an existing preference captured by the structure predictors?